Last update Sept. 17, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Pizotifen is also known as
Pizotifen in other languages or writings:
Main tradenames from several countries containing Pizotifen in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 78 | % |
Molecular weight | 295 | daltons |
Protein Binding | 90 | % |
VD | 11.9 | l/Kg |
Tmax | 5 | hours |
T½ | 23 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Pizotifen is a sedative antihistamine with weak antimuscarinic properties and a potent serotonin and tryptamine antagonist indicated for migraine prophylaxis. It is also used as an appetite stimulant. Oral administration in one to three daily doses.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (very high percentage of protein binding and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Davanzo 2014), especially during the neonatal period and in the event of prematurity.